Brian Burkavage was named Senior Vice President, Finance of Damora Therapeutics, Inc. As of November 6, 2026, Damora Therapeutics, Inc. has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on May 4, 2026, naming 1 appointment (Form 8-K, May 4, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Damora Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Damora Therapeutics, Inc. reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-05-04. It names 1 person. Every row below is cited to the filing it comes from, and this page adds each new change as Damora Therapeutics, Inc. files it.
Also on the record for Damora Therapeutics, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| July 28, 2026 | Stake report, Schedule 13G, by BlackRock, Inc. | 5.1% of the class | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G, by Avoro Capital Advisors LLC | 6.27% of the class | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G/A, by Jain Global LLC | — | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G/A, by Point72 Asset Management, L.P. | 2% of the class | 5%+ stakes | Source |
| April 23, 2026 | Stake report, Schedule 13G/A, by Paragon Therapeutics, Inc. | 3.39% of the class | 5%+ stakes | Source |
| April 23, 2026 | Stake report, Schedule 13G/A, by Paramora Holding LLC | 3.39% of the class | 5%+ stakes | Source |
| March 6, 2026 | Stake report, Schedule 13G/A, by Ikarian Capital, LLC | 0.6% of the class | 5%+ stakes | Source |
| February 17, 2026 | Stake report, Schedule 13G, by Jain Global LLC | 7.5% of the class | 5%+ stakes | Source |
| February 17, 2026 | Stake report, Schedule 13G, by Venrock Healthcare Capital Partners III, L.P. | 6% of the class | 5%+ stakes | Source |
| February 11, 2026 | Stake report, Schedule 13D/A, by Fairmount Funds Management LLC | 19.99% of the class | 5%+ stakes | Source |
| January 12, 2026 | Stake report, Schedule 13G, by Paragon Therapeutics, Inc. | 7.5% of the class | 5%+ stakes | Source |
| January 12, 2026 | Stake report, Schedule 13G, by Paramora Holding LLC | 7.5% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Damora Therapeutics, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Damora Therapeutics, Inc. and the records around it.
Damora Therapeutics, Inc. elsewhere on the record
- 5%+ stake filings Jul 2026
- Form D filing Nov 2025
- Who owns it
Companies that share a holder
- Jain Global LLC also filed stake reports on 3 other companies: M3-Brigade Acquisition V Corp. (Mar 2026), 1RT Acquisition Corp. (Nov 2025), INFINITY NATURAL RESOURCES, INC. (Aug 2025)
- Novo Holdings A/S also filed stake reports on 11 other companies: Avalyn Pharma Inc. (Aug 2026), Hemab Therapeutics Holdings, Inc. (Aug 2026), Obsidian Therapeutics, Inc. (Aug 2026)
- Fairmount Funds Management LLC also filed stake reports on 13 other companies: Alaunos Therapeutics, Inc. (Oct 2026), SPYRE THERAPEUTICS, INC. (Oct 2026), Korsana Biosciences, Inc. (Sep 2026)
Watch Damora Therapeutics, Inc.
Get an email when Damora Therapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Damora Therapeutics, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Damora Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Damora Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
13 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
The newest 12 of 19 records.
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-05-04 | In | Senior Vice President, Finance | 8-K, 2026-05-04 |
Who leads Damora Therapeutics, Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Senior Vice President, Finance: Brian Burkavage, appointed (filed 2026-05-04).
New leaders reset buying decisions — get the Full Report on Damora Therapeutics, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Senior Vice President, Finance at Damora Therapeutics, Inc., with the record behind each one.
Find candidates like Finance at Damora Therapeutics, Inc.Every change, in the filing's words
Appointed: Brian Burkavage, Senior Vice President, Finance
On April 28, 2026, the Board appointed Brian Burkavage, the Company's current Senior Vice President, Finance, to serve as the Company's principal financial officer and principal accounting officer, effective as of the Effective Time.
- Departure of Chief Financial Officer On April 28, 2026, the Board of Directors (the "Board") of Damora Therapeutics, Inc. (the "Company") determined that, effective as of May 1, 2026 (the "Effective Time"), Lori Firmani would cease serving as the Company's Chief Financial Officer.
- Ms. Firmani had served as the Company's principal financial officer and principal accounting officer since August 2024, prior to the Company's acquisition of privately-held Damora Therapeutics, Inc. in November 2025.
- Prior to joining the Company in December 2025, Mr. Burkavage served as Senior Vice President, Finance and Chief Accounting Officer and VP, Finance at IO Biotech, Inc. from November 2021 to December 2025.
- Prior to that, he served as the Controller at Passage Bio, Inc. from 2020 to 2021, and Director of Financial Planning and Analysis at Aclaris Therapeutics, Inc. from 2017 to 2020.
- Earlier in his career, he spent 11 years at Ernst & Young LLP in roles of increasing responsibility within the financial statement audit practice.
- Mr. Burkavage earned his B.A. and M.S.A. from the University of Notre Dame and is a licensed Certified Public Accountant.
Tools for this story
Each opens in a new tab, filled in for Damora Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.